Sanofi names Gary Nabel chief scientific officer for global R&D

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.

Sanofi names Gary Nabel chief scientific officer for global R&D

Sanofi ($SNY) appointed Dr. Gary J. Nabel as chief scientific officer, senior vice president and deputy to the president for global R&D. Nabel, who will be based in Cambridge, MA, joins the company from the National Institutes of Health, where he served as director of the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases since 1999. In his new role, Nabel will assess and coordinate Sanofi's scientific direction for biopharmaceuticals, vaccines and animal health. "I am very excited that Dr. Nabel will join Sanofi's R&D organization, said Dr. Elias Zerhouni, president of global R&D. "Our challenges today require that we re-invent our R&D model. Gary's experience will be invaluable to help us achieve this goal. Story | Release

Gary Nabel--Sanofi
Nabel will serve as chief scientific officer and deputy to the president for global R&D.

Charles M. Baum--MethylGene
Baum will serve as president and CEO.


> MethylGene appointed Charles M. Baum as president and CEO. Release

> Starpharma Vice President Malcolm McColl will serve as CEO of Viralytics. Release

> Alimera Sciences ($ALIM) appointed a management team that will oversee European commercialization of its lead product, Iluvien: Philip Ashman was named senior vice president and European managing director; Eric Teo will serve as vice president and European medical director; and Anne-Marie Swift will serve as vice president and European marketing director. Release

> Biota Pharmaceuticals ($BOTA) tapped Russell Plumb to be its CEO and Joseph Patti to serve as its executive vice president of corporate development and strategy. Early this year Plumb and Patti sold their last company, Inhibitex, to Bristol-Myers Squibb ($BMY) for a cool $2.5 billion, much of which Bristol wrote off after axing development of a hepatitis C pill from Inhibitex because of a safety disaster in mid-stage development that involved a patient death and hospitalizations.  Release

> Amarantus BioSciences appointed Robert J. Zimmerman as product development adviser. Release

> Oncolytics Biotech ($ONCY) appointed Kirk Look as chief financial officer. Release

> Cell Therapeutics ($CTIC) appointed Monique Greer as senior vice president of corporate communications and investor relations. Release

> Chimerix appointed Michelle Berrey as chief medical officer. Release

> Oncos Therapeutics appointed Frans Wuite as president and CEO. Release

> Immatics appointed Peter Chambré as chairman of the board, effective immediately. Release

Medical Devices

> ConforMIS appointed Peter Traynor as CFO. Release

> Tornier ($TRNX) appointed David H. Mowry as interim president and CEO. Mowry succeeds Douglas W. Kohrs, who retired as president, CEO and executive director. Release

> Stryker ($SYK) appointed David Floyd as group president of orthopedics. Release


> Johnson & Johnson ($JNJ) appointed Dr. A. Eugene Washington to its board of directors. Release

> Dendreon ($DNDN) appointed Lindsay Rocco as executive vice president of corporate communications. Release

> Shire ($SHPG) named Jeff Jonas president of the company's regenerative medicine business. Release

Regenerative Medicine

> The Alliance for Regenerative Medicine elected Geoff MacKay, president and CEO of Organogenesis, as the next chair, and Keith Murphy, chairman and CEO or Organovo, as vice-chair. Ed Field, COO of Cytomedix, and Martin McGlynn, president and CEO of StemCells, were elected to the two other officer positions. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.